Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction

URN to cite this document:: urn:nbn:de:bvb:355-epub-515334
DOI to cite this document:: 10.5283/epub.51533

Pabel, Steffen ; Hamdani, Nazha ; Singh, Jagdeep ; Sossalla, Samuel

Preview

License: Creative Commons Attribution 4.0
PDF - Published Version
(2MB)

Date of publication of this fulltext: 27 Jan 2022 15:03

Alternative links to fulltext:DOI Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

Heart failure with preserved ejection fraction (HFpEF) is an unsolved and growing concern in cardiovascular medicine. While no treatment options that improve prognosis in HFpEF patients has been established so far, SGLT2 inhibitors (SGLT2i) are currently being investigated for the treatment of HFpEF patients. SGLT2i have already been shown to mitigate comorbidities associated with HFpEF such as ...